The pre-panel meeting word from the FDA in online satraplatin briefing documents that walloped GPC Biotech Inc.'s shares - denting licensee Spectrum Pharmaceuticals Inc. and GPC partner Pharmion Corp. as well - could mean a delay of the prostate cancer drug's approval, and for how long is unclear.(BioWorld Today)

Geron Corp.'s steady news trickle this summer presages a stronger flow as the year goes on, and an "analyst day" last week got a hosted peek into what's ahead next year, leaving Geron watchers optimistic but reservedly so. (BioWorld Financial Watch)